Inactivated vaccines. 2. Laboratory indices of protection
Identifieur interne : 000702 ( Istex/Corpus ); précédent : 000701; suivant : 000703Inactivated vaccines. 2. Laboratory indices of protection
Auteurs : W. R. Dowdle ; M. T. Coleman ; S. R. Mostow ; H. S. Kaye ; S. C. SchoenbaumSource :
- Postgraduate Medical Journal [ 0032-5473 ] ; 1973-03.
English descriptors
- Teeft :
- Aichi, Aichi vaccine, Aichi vaccine recipients, Aichi vaccinees, American journal, Attack rate, Attack rates, Control group, Epidemic strain, General virology, Hong kong, Hong kong epidemic, Illness categories, Influenza, Influenza vaccine, Influenza vaccine field trials, Influenza vaccines, Nasal secretions, Neuraminidase, Neuraminidase antigens, Neuraminidase inhibition, Neuraminidase serum antibodies, Percent reduction, Postvaccine, Postvaccine aichi, Present address, Protective effect, Serodiagnosis, Serologic evidence, Serum antibodies, Serum haemagglutination inhibition, Serum neuraminidase inhibition, Titre, Vaccine, Vaccine efficacy, Vaccine groups, Vaccine recipients, Vaccinee, World health organization, Zonal centrifugation.
Abstract
The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.
Url:
DOI: 10.1136/pgmj.49.569.159
Links to Exploration step
ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><author><name sortKey="Dowdle, W R" sort="Dowdle, W R" uniqKey="Dowdle W" first="W. R." last="Dowdle">W. R. Dowdle</name></author><author><name sortKey="Coleman, M T" sort="Coleman, M T" uniqKey="Coleman M" first="M. T." last="Coleman">M. T. Coleman</name></author><author><name sortKey="Mostow, S R" sort="Mostow, S R" uniqKey="Mostow S" first="S. R." last="Mostow">S. R. Mostow</name></author><author><name sortKey="Kaye, H S" sort="Kaye, H S" uniqKey="Kaye H" first="H. S." last="Kaye">H. S. Kaye</name></author><author><name sortKey="Schoenbaum, S C" sort="Schoenbaum, S C" uniqKey="Schoenbaum S" first="S. C." last="Schoenbaum">S. C. Schoenbaum</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9</idno><date when="1973" year="1973">1973</date><idno type="doi">10.1136/pgmj.49.569.159</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000702</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000702</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><author><name sortKey="Dowdle, W R" sort="Dowdle, W R" uniqKey="Dowdle W" first="W. R." last="Dowdle">W. R. Dowdle</name></author><author><name sortKey="Coleman, M T" sort="Coleman, M T" uniqKey="Coleman M" first="M. T." last="Coleman">M. T. Coleman</name></author><author><name sortKey="Mostow, S R" sort="Mostow, S R" uniqKey="Mostow S" first="S. R." last="Mostow">S. R. Mostow</name></author><author><name sortKey="Kaye, H S" sort="Kaye, H S" uniqKey="Kaye H" first="H. S." last="Kaye">H. S. Kaye</name></author><author><name sortKey="Schoenbaum, S C" sort="Schoenbaum, S C" uniqKey="Schoenbaum S" first="S. C." last="Schoenbaum">S. C. Schoenbaum</name></author></analytic><monogr></monogr><series><title level="j">Postgraduate Medical Journal</title><title level="j" type="abbrev">Postgrad Med J</title><idno type="ISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><imprint><publisher>The Fellowship of Postgraduate Medicine</publisher><date type="published" when="1973-03">1973-03</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">569</biblScope><biblScope unit="page" from="159">159</biblScope></imprint><idno type="ISSN">0032-5473</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0032-5473</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Aichi</term><term>Aichi vaccine</term><term>Aichi vaccine recipients</term><term>Aichi vaccinees</term><term>American journal</term><term>Attack rate</term><term>Attack rates</term><term>Control group</term><term>Epidemic strain</term><term>General virology</term><term>Hong kong</term><term>Hong kong epidemic</term><term>Illness categories</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza vaccine field trials</term><term>Influenza vaccines</term><term>Nasal secretions</term><term>Neuraminidase</term><term>Neuraminidase antigens</term><term>Neuraminidase inhibition</term><term>Neuraminidase serum antibodies</term><term>Percent reduction</term><term>Postvaccine</term><term>Postvaccine aichi</term><term>Present address</term><term>Protective effect</term><term>Serodiagnosis</term><term>Serologic evidence</term><term>Serum antibodies</term><term>Serum haemagglutination inhibition</term><term>Serum neuraminidase inhibition</term><term>Titre</term><term>Vaccine</term><term>Vaccine efficacy</term><term>Vaccine groups</term><term>Vaccine recipients</term><term>Vaccinee</term><term>World health organization</term><term>Zonal centrifugation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</div></front></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>aichi</json:string><json:string>vaccine</json:string><json:string>neuraminidase</json:string><json:string>vaccinee</json:string><json:string>postvaccine</json:string><json:string>attack rates</json:string><json:string>serodiagnosis</json:string><json:string>influenza</json:string><json:string>influenza vaccines</json:string><json:string>attack rate</json:string><json:string>titre</json:string><json:string>aichi vaccine recipients</json:string><json:string>neuraminidase antigens</json:string><json:string>aichi vaccinees</json:string><json:string>hong kong</json:string><json:string>american journal</json:string><json:string>neuraminidase inhibition</json:string><json:string>vaccine recipients</json:string><json:string>control group</json:string><json:string>aichi vaccine</json:string><json:string>influenza vaccine</json:string><json:string>illness categories</json:string><json:string>protective effect</json:string><json:string>nasal secretions</json:string><json:string>percent reduction</json:string><json:string>epidemic strain</json:string><json:string>serologic evidence</json:string><json:string>vaccine efficacy</json:string><json:string>postvaccine aichi</json:string><json:string>serum haemagglutination inhibition</json:string><json:string>neuraminidase serum antibodies</json:string><json:string>present address</json:string><json:string>vaccine groups</json:string><json:string>serum neuraminidase inhibition</json:string><json:string>serum antibodies</json:string><json:string>hong kong epidemic</json:string><json:string>general virology</json:string><json:string>influenza vaccine field trials</json:string><json:string>zonal centrifugation</json:string><json:string>world health organization</json:string></teeft></keywords><author><json:item><name>W. R. Dowdle</name></json:item><json:item><name>M. T. Coleman</name></json:item><json:item><name>S. R. Mostow</name></json:item><json:item><name>H. S. Kaye</name></json:item><json:item><name>S. C. Schoenbaum</name></json:item></author><arkIstex>ark:/67375/NVC-73VZGDX5-9</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>research-article</json:string></originalGenre><abstract>The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</abstract><qualityIndicators><score>6.582</score><pdfWordCount>2542</pdfWordCount><pdfCharCount>16916</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>502.08 x 684 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>170</abstractWordCount><abstractCharCount>1108</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Inactivated vaccines. 2. Laboratory indices of protection</title><pmid><json:string>4803439</json:string></pmid><genre><json:string>research-article</json:string></genre><host><title>Postgraduate Medical Journal</title><language><json:string>unknown</json:string></language><issn><json:string>0032-5473</json:string></issn><eissn><json:string>1469-0756</json:string></eissn><volume>49</volume><issue>569</issue><pages><first>159</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1968</json:string><json:string>1973-03-01</json:string><json:string>3000</json:string></date><geogName></geogName><orgName><json:string>Peter Bent Brigham Hospital, Boston, Massachusetts</json:string><json:string>Cleveland Metropolitan General Hospital, Cleveland, Ohio</json:string><json:string>Georgia State Prison</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Hong Kong</json:string><json:string>W. R. Dowdle</json:string><json:string>In</json:string><json:string>Mostow</json:string><json:string>M.D. Center</json:string></persName><placeName><json:string>Hong Kong</json:string><json:string>Georgia</json:string><json:string>Japan</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Rossen, Kasel & Couch, 1971</json:string><json:string>Fazekas de St Groth & Donnelly, 1950</json:string><json:string>Webster & Pereira, 1968</json:string><json:string>Schoenbaum et al., 1969</json:string><json:string>Edmondson et al. (1971)</json:string><json:string>Davenport, 1967</json:string><json:string>Rapmund et al. (1959)</json:string><json:string>March 1973</json:string><json:string>W. R. Dowdle et al.</json:string><json:string>Hierholzer, Suggs & Hall, 1969</json:string><json:string>Francis et al., 1943</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-73VZGDX5-9</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, general & internal</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - clinical medicine</json:string><json:string>3 - general & internal medicine</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - General Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>1973</publicationDate><copyrightDate>1973</copyrightDate><doi><json:string>10.1136/pgmj.49.569.159</json:string></doi><id>16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">The Fellowship of Postgraduate Medicine</publisher><availability><licence><p>© British Medical Journal Publishing Group</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>1973-03-01</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Presented by the senior author before the symposium on Influenza Vaccines, London, 27 April 1972.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><author xml:id="author-0000"><persName><forename type="first">W. R.</forename><surname>Dowdle</surname></persName></author><author xml:id="author-0001"><persName><forename type="first">M. T.</forename><surname>Coleman</surname></persName></author><author xml:id="author-0002"><persName><forename type="first">S. R.</forename><surname>Mostow</surname></persName></author><author xml:id="author-0003"><persName><forename type="first">H. S.</forename><surname>Kaye</surname></persName></author><author xml:id="author-0004"><persName><forename type="first">S. C.</forename><surname>Schoenbaum</surname></persName></author><idno type="istex">16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9</idno><idno type="ark">ark:/67375/NVC-73VZGDX5-9</idno><idno type="DOI">10.1136/pgmj.49.569.159</idno><idno type="href">postgradmedj-49-159.pdf</idno><idno type="PMID">4803439</idno><idno type="local">postgradmedj;49/569/159</idno></analytic><monogr><title level="j">Postgraduate Medical Journal</title><title level="j" type="abbrev">Postgrad Med J</title><idno type="pISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><idno type="PublisherID-hwp">postgradmedj</idno><idno type="PublisherID-nlm-ta">Postgrad Med J</idno><imprint><publisher>The Fellowship of Postgraduate Medicine</publisher><date type="published" when="1973-03"></date><biblScope unit="volume">49</biblScope><biblScope unit="issue">569</biblScope><biblScope unit="page" from="159">159</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1973-03-01</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</p></abstract></profileDesc><revisionDesc><change when="1973-03-01">Created</change><change when="1973-03">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-17">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">postgradmedj</journal-id><journal-id journal-id-type="nlm-ta">Postgrad Med J</journal-id><journal-title>Postgraduate Medical Journal</journal-title><abbrev-journal-title abbrev-type="publisher">Postgrad Med J</abbrev-journal-title><issn pub-type="ppub">0032-5473</issn><issn pub-type="epub">1469-0756</issn><publisher><publisher-name>The Fellowship of Postgraduate Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">4803439</article-id><article-id pub-id-type="other">postgradmedj;49/569/159</article-id><article-id pub-id-type="doi">10.1136/pgmj.49.569.159</article-id><article-id pub-id-type="other">159</article-id><article-id pub-id-type="other">pgmj.49.569.159</article-id><article-categories><subj-group subj-group-type="heading"><subject>Influenza Vaccines</subject></subj-group></article-categories><title-group><article-title>Inactivated vaccines. 2. Laboratory indices of protection<xref ref-type="fn" rid="fn1">*</xref></article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dowdle</surname><given-names>W. R.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Coleman</surname><given-names>M. T.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mostow</surname><given-names>S. R.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Kaye</surname><given-names>H. S.</given-names></name></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Schoenbaum</surname><given-names>S. C.</given-names></name></contrib></contrib-group><author-notes><fn id="fn1"><label>*</label><p>Presented by the senior author before the symposium on Influenza Vaccines, London, 27 April 1972.</p></fn></author-notes><pub-date pub-type="ppub"><month>03</month><year>1973</year></pub-date><pub-date pub-type="epub"><day>1</day><month>3</month><year>1973</year></pub-date><volume>49</volume><volume-id pub-id-type="other">49</volume-id><volume-id pub-id-type="other">49</volume-id><issue>569</issue><issue-id pub-id-type="other">postgradmedj;49/569</issue-id><issue-id pub-id-type="other">569</issue-id><issue-id pub-id-type="other">49/569</issue-id><fpage>159</fpage><self-uri content-type="pdf" xlink:role="full-text" xlink:href="postgradmedj-49-159.pdf"></self-uri><abstract><p>The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</p></abstract></article-meta></front></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Inactivated vaccines. 2. Laboratory indices of protection</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Inactivated vaccines. 2. Laboratory indices of protection*</title></titleInfo><name type="personal"><namePart type="given">W. R.</namePart><namePart type="family">Dowdle</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M. T.</namePart><namePart type="family">Coleman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. R.</namePart><namePart type="family">Mostow</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H. S.</namePart><namePart type="family">Kaye</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S. C.</namePart><namePart type="family">Schoenbaum</namePart><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="research-article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>The Fellowship of Postgraduate Medicine</publisher><dateIssued encoding="w3cdtf">1973-03</dateIssued><dateCreated encoding="w3cdtf">1973-03-01</dateCreated><copyrightDate encoding="w3cdtf">1973</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</abstract><note type="footnotes">Presented by the senior author before the symposium on Influenza Vaccines, London, 27 April 1972.</note><relatedItem type="host"><titleInfo><title>Postgraduate Medical Journal</title></titleInfo><titleInfo type="abbreviated"><title>Postgrad Med J</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0032-5473</identifier><identifier type="eISSN">1469-0756</identifier><identifier type="PublisherID-hwp">postgradmedj</identifier><identifier type="PublisherID-nlm-ta">Postgrad Med J</identifier><part><date>1973</date><detail type="volume"><caption>vol.</caption><number>49</number></detail><detail type="issue"><caption>no.</caption><number>569</number></detail><extent unit="pages"><start>159</start></extent></part></relatedItem><identifier type="istex">16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9</identifier><identifier type="ark">ark:/67375/NVC-73VZGDX5-9</identifier><identifier type="DOI">10.1136/pgmj.49.569.159</identifier><identifier type="href">postgradmedj-49-159.pdf</identifier><identifier type="PMID">4803439</identifier><identifier type="local">postgradmedj;49/569/159</identifier><accessCondition type="use and reproduction" contentType="copyright">© British Medical Journal Publishing Group</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>© British Medical Journal Publishing Group</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000702 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000702 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9
|texte= Inactivated vaccines. 2. Laboratory indices of protection
}}
| This area was generated with Dilib version V0.6.33. |  |